Company: ABBV
Filing Date: 2025-02-18
Form Type: 424B5
Source: 0001104659-25-014554
Chunk: 62

Company: AbbVie Inc.
Filing Date: 2025-02-18
Form: 424B5
Chunk 62
---
2024, which has been filed with the Securities and Exchange Commission. AbbVie notes these factors for investors as permitted by the PSLRA. AbbVie does not undertake, and specifically declines, any obligation to update the forward-looking statements included in this prospectus supplement to reflect events or circumstances after the date hereof, unless AbbVie is required by applicable securities law to do so.

<div align='center'>S-41</div>

TABLE OF CONTENTS

### LEGAL MATTERS
Certain legal matters related to the offering will be passed upon for us by Wachtell, Lipton, Rosen & Katz, New York, New York. Certain legal matters related to the offering will be passed upon for the underwriters by Davis Polk & Wardwell LLP, New York, New York.

<div align='center'>S-42</div>

TABLE OF CONTENTS

### EXPERTS
The consolidated financial statements of AbbVie Inc. appearing in our Annual Report on Form 10-K for the year ended December 31, 2024, and the effectiveness of the Company’s internal control over financial reporting as of December 31, 2024, have been audited by Ernst & Young LLP, independent registered public accounting firm, as set forth in their reports thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.

<div align='center'>S-43</div>

TABLE OF CONTENTS

### PROSPECTUS

#### ABBVIE INC.

#### Debt Securities
This prospectus relates to the sale of one or more series of debt securities of AbbVie Inc., a Delaware corporation (“AbbVie,” “we,” “us” or the “Company”), from time to time, on terms and at prices determined at the time the debt securities are offered for sale. The terms and prices will be described in more detail in one or more supplements to this prospectus. Before investing, you should carefully read this prospectus and any related prospectus supplement or free writing prospectus. Prospectus supplements or free writing prospectuses may also add, update, or change information contained in this prospectus.

We may offer and sell these securities to or through agents, underwriters, dealers, or directly to purchasers on a continuous or a delayed basis. The names of any agents, underwriters, or dealers and the terms of the arrangements with such entities will be